Ontology highlight
ABSTRACT:
SUBMITTER: Agosto C
PROVIDER: S-EPMC8491612 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
Agosto Caterina C Salamon Eleonora E Giacomelli Luca L Papa Simonetta S Benedetti Francesca F Benini Franca F
Frontiers in neurology 20210921
Nusinersen is the first oligonucleotide-based drug that is approved for the treatment of spinal muscular atrophy. In January 2020, the WHO declared COVID-19 a pandemic and nusinersen-provider centers had to postpone planned infusions for some children along with other related interventions. Considering the important contribution that the intrathecal infusions and other support activities could have on the quality of life of spinal muscular atrophy patients and their families, this emergency coul ...[more]